{"schema_version":"secwatch.filing_event.v1","accession":"0001701478-26-000014","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2026-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.934369+00:00","generated_at":"2026-05-15T23:06:27.505815+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Azitra reports FY2025 net loss of $11.0M, cash $2.1M; pipeline advances","bullets":["Net loss widened to $11.0M in FY2025 from $9.0M in FY2024; R&D $4.8M, G&A $6.2M.","Cash and equivalents of $2.1M as of Dec 31, 2025; completed $8.5M in financings during the year.","First patient dosed in Phase 1/2 trial for ATR-04 (EGFRi rash); Fast Track from FDA.","Topline data expected H2 2026 for ATR-12 (Netherton syndrome) and mid-2026 for ATR-04.","Positive preclinical data for ATR-01 (ichthyosis vulgaris); IND-enabling studies continue in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001701478-26-000014","json":"https://secwatch.observer/filing/0001701478-26-000014.json","markdown":"https://secwatch.observer/filing/0001701478-26-000014.md","text":"https://secwatch.observer/filing/0001701478-26-000014.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/0001701478-26-000014-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000170147826000014/aztr-20260227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:06:27.505815+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}